Last updated: February 13, 2026
What Is the Market Profile for NDC 43975-0315?
The drug with NDC 43975-0315 is a biosimilar version of trastuzumab, an antibody used to treat HER2-positive breast and gastric cancers. It is marketed under the brand name Kanjinti by Amgen. The product entered the US market in 2019 after gaining FDA approval and was designed to offer a cost-effective alternative to Herceptin (Genentech/Roche).
What Is the Current Market Size and Penetration?
The trastuzumab market was valued at approximately $4.6 billion globally in 2022, with the US accounting for roughly 60% of sales, or about $2.76 billion (source: IQVIA). Biosimilars have gained market share since 2019, driven by cost savings and patent expirations of originator biologics.
In the US, Kanjinti's market share reached 10-15% by 2022, with sales estimates between $400 million and $600 million. It competes primarily against Herceptin, which held over 70% of the US HER2-positive breast cancer market as of 2022.
How Does the Pricing of NDC 43975-0315 Compare?
Initial launch pricing for Kanjinti was approximately 15-20% lower than Herceptin. The average wholesale price (AWP) of Herceptin was about $2,600 per 440 mg vial in 2022, while Kanjinti's AWP was roughly $2,100–$2,200 per vial.
Price trends since market entry:
-
Biosimilar prices generally decline 10-15% annually as more competitors enter.
-
Kanjinti's price has decreased by approximately 10% since 2019, aligning with typical biosimilar market dynamics.
What Are the Key Factors Impacting Future Price and Marketshare?
Patent Litigation and Market Access
The originator Herceptin's patents expired in the US by 2019 but faced ongoing legal challenges in some formulations, affecting biosimilar entry and market access. Future patent litigations could influence biosimilar pricing and capacity to expand market share.
Number of Biosimilar Competitors
Multiple biosimilars entered in 2019-2020, including Pfizer's Trazimera and Samsung's Herzuma, intensifying price competition. As of 2023, more biosimilars aim to enter, which could drive prices further downward.
Payer and Provider Adoption
Insurance formulary preferences favor biosimilars to contain costs. Managed care organizations increasingly prefer biosimilars, which may push prices lower and improve biosimilar market penetration.
Regulatory and Reimbursement Policies
CMS policies favor biosimilars in the Medicare program. Reimbursement pathways are aligned to encourage biosimilar adoption. Future policy changes could influence pricing strategies.
What Are The Price Projections for NDC 43975-0315?
Short to Mid-Term Predictions (Next 2 Years)
-
Biosimilar prices are expected to decrease further by about 5-10% annually.
-
Wholesale acquisition prices (WAC) for Kanjinti could fall to $1,900–$2,000 per vial by 2025.
-
Market share could increase marginally to 20-25%, driven by payer incentives and increasing clinician familiarity.
Longer-Term Projections (3-5 Years)
-
Continued price erosion is likely, with biosimilars potentially trading at a 25-30% discount to originator brand prices.
-
Price levels could stabilize around $1,600–$1,800 per vial if generic competition intensifies and reimbursement structures favor biosimilars.
-
Market share of biosimilars like Kanjinti could reach 35-50%, especially if patent challenges resolve favorably and newer biosimilars receive approval.
Factors Influencing Price and Market Share
-
Entry of additional biosimilars reduces prices and increases market share.
-
Patent expiry battles could lead to price volatility or delayed biosimilar penetration.
-
Payer policies and regional uptake influence pricing adjustments and market penetration rates.
Summary Metrics Table
| Year |
Expected Biosimilar Price (Per Vial) |
Estimated US Market Share |
Remarks |
| 2023 |
$2,100–$2,200 |
10–15% |
Initial prices, growing competition |
| 2024 |
$2,000–$2,100 |
15–20% |
Increased biosimilar entry, payer support |
| 2025 |
$1,900–$2,000 |
20–25% |
Market stabilization, further biosimilar approvals |
| 2026–2028 |
$1,600–$1,800 |
35–50% |
Expanded biosimilar market penetration |
Key Takeaways
- NDC 43975-0315 (Kanjinti) entered the US market in 2019 as a biosimilar to Herceptin, with an initial 15-20% discount.
- Biosimilar prices are trending downward, with forecasted reductions of 5-10% per year over the next two years.
- Market share has increased from 10-15% in 2022 to an estimated 20-25% by 2025, with potential for further growth.
- Pricing and market penetration are influenced by patent disputes, competition, payer policies, and regional adoption.
- Prices are expected to stabilize around $1,600–$1,800 per vial by 2028, with biosimilar market share surpassing 50% under favorable conditions.
FAQs
1. How does the pricing of biosimilars like NDC 43975-0315 compare to the originator Herceptin?
Biosimilars like Kanjinti launched at approximately 15-20% lower wholesale prices. Prices tend to decrease further due to competition, potentially reaching about 25-30% off the originator by 2028.
2. What factors could accelerate the price decline for this biosimilar?
Introduction of additional biosimilars, aggressive payer formulary preferences favoring biosimilars, and patent litigation outcomes are key factors.
3. What is the likelihood of biosimilar market share surpassing 50% for trastuzumab?
High if biosimilar price reductions and payer incentives continue; could materialize within five years if new biosimilars obtain approval and patent issues resolve favorably.
4. How do regional differences affect pricing and adoption?
Regions with strong payer support and regulatory incentives for biosimilars tend to see faster adoption and lower prices, whereas some markets are slower to transition from originators.
5. Are there specific regulatory barriers affecting the biosimilar market for trastuzumab?
Yes. Patent litigation, biologic exclusivity periods, and complex manufacturing requirements can delay biosimilar entry and impact pricing strategies.
References
[1] IQVIA. Top-Line Market Data for Oncology Drugs, 2022.
[2] FDA. Biologics License Application Approval for Kanjinti (trastuzumab-anns), 2019.
[3] Amgen. Kanjinti Prescribing Information, 2019.
